S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:OCX

OncoCyte (OCX) Stock Forecast, Price & News

$0.22
-0.01 (-4.36%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.21
$0.23
50-Day Range
$0.21
$0.27
52-Week Range
$0.20
$1.35
Volume
369,127 shs
Average Volume
233,045 shs
Market Capitalization
$36.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.11

OncoCyte MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
406.6% Upside
$1.11 Price Target
Short Interest
Healthy
0.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of OncoCyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$8.25 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.28) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

209th out of 983 stocks

Diagnostic Substances Industry

6th out of 15 stocks


OCX stock logo

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
OncoCyte (NYSE:OCX) Now Covered by Analysts at StockNews.com
OncoCyte Q1 2023 Earnings Preview
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
OncoCyte (OCX) to Release Earnings on Thursday
OncoCyte (NYSE:OCX) Coverage Initiated at StockNews.com
StockNews.com Initiates Coverage on OncoCyte (NYSE:OCX)
OncoCyte (NYSE:OCX) Now Covered by StockNews.com
Oncocyte Presents New Data at AACR
Oncocyte Reduces Workforce By 20%
Oncocyte Announces Reduction in Force
Broadwood Partners Now Owns 33.3% of OncoCyte
OncoCyte (NASDAQ:OCX) PT Lowered to $0.45
See More Headlines

OCX Price History

OCX Company Calendar

Last Earnings
11/09/2021
Today
6/03/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.11
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$0.45
Forecasted Upside/Downside
+406.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-72,900,000.00
Net Margins
-787.97%
Pretax Margin
-1,056.00%

Debt

Sales & Book Value

Annual Sales
$960,000.00
Cash Flow
$0.04 per share
Book Value
$0.32 per share

Miscellaneous

Free Float
111,347,000
Market Cap
$36.19 million
Optionable
Optionable
Beta
1.58

Key Executives

  • Joshua Riggs
    President, Chief Executive Officer & Director
  • Anish John
    Chief Financial Officer & Senior Vice President
  • Ekkehard Schütz
    Chief Science Officer
  • Yuh-Min Chiang
    Senior Vice President-Research & Development
  • Padma Sundar
    Chief Commercial Officer













OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price forecast for 2023?

3 analysts have issued 12 month price targets for OncoCyte's stock. Their OCX share price forecasts range from $0.45 to $3.00. On average, they anticipate the company's share price to reach $1.11 in the next year. This suggests a possible upside of 406.6% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $0.3209 on January 1st, 2023. Since then, OCX stock has decreased by 31.6% and is now trading at $0.2196.
View the best growth stocks for 2023 here
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our OCX earnings forecast
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The company earned $0.98 million during the quarter, compared to analyst estimates of $3.20 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 34.08%.

What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (1.98%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends
.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $0.22.

How much money does OncoCyte make?

OncoCyte (NASDAQ:OCX) has a market capitalization of $36.19 million and generates $960,000.00 in revenue each year.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -